Gamifant

Land: Evrópusambandið

Tungumál: tékkneska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Download Opinber matsskýrsla (PAR)
19-03-2021

Virkt innihaldsefni:

Emapalumab

Fáanlegur frá:

Swedish Orphan Biovitrum AB (publ)

ATC númer:

L04AA39

INN (Alþjóðlegt nafn):

emapalumab

Lækningarsvæði:

Immune System Diseases

Ábendingar:

Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).

Leyfisstaða:

Odmítl

Skjöl á öðrum tungumálum

Opinber matsskýrsla Opinber matsskýrsla búlgarska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla spænska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla danska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla þýska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla eistneska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla gríska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla enska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla franska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla ítalska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla lettneska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla litháíska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla ungverska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla maltneska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla hollenska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla pólska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla portúgalska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla rúmenska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla slóvenska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla finnska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla sænska 19-03-2021
Opinber matsskýrsla Opinber matsskýrsla króatíska 19-03-2021

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu